- GLP-1 News
- Posts
- GLP-1 News for Thursday, November 21, 2024
GLP-1 News for Thursday, November 21, 2024
Ozempic for Weight Loss: Best and Worst Thanksgiving Foods to Eat | What RFK Jr. Has Said About Ozempic the Popular Weight Loss Drug | Over 50% of U.S. Adults Qualify for Ozempic, Wegovy | How to Qualify for Ozempic With Insurance: New Study

What we’re hearing
GLP-1 drugs like Ozempic and Wegovy are making a significant impact on health, industry, and society. Over half of U.S. adults are now eligible for these medications, which are used not only for weight loss but also for managing diabetes and preventing cardiovascular disease. Their benefits extend beyond slimming down, with studies showing reduced risks of liver disease, heart failure, and even addiction. In one notable trial, Mounjaro (tirzepatide) demonstrated a remarkable 94% reduction in diabetes risk. GLP-1 drugs are also being explored for other conditions, such as PCOS and alcohol use disorder.
Despite their promise, these drugs face challenges. High costs and limited insurance coverage make them inaccessible to many, with only 25% of Americans having insurance that covers them, predominantly through Medicaid. Additionally, a large percentage of users—up to 75%—discontinue these medications within a year due to expense, side effects, or misunderstandings about long-term use. Some users experience muscle loss, prompting experts to stress the importance of proper nutrition and exercise while on these treatments.
The growing popularity of GLP-1 drugs is also disrupting the food industry. Many users report losing their taste for ultraprocessed snacks, gravitating instead toward fresh, natural foods. This shift is pushing companies to innovate, with firms like Mattson developing GLP-1-friendly products such as high-protein brownies and fiber-enriched snacks. Meanwhile, other industries, such as beer and candy, are adapting to changing consumer behavior, and even Walmart has seen a decline in sales of traditional weight-loss products.
Looking ahead, innovation in weight-loss treatments continues to accelerate. New medications like CagriSema and oral alternatives to injectables are on the horizon, offering greater convenience and expanded options for patients. Researchers are also exploring precision medicine to tailor treatments to individual needs while minimizing side effects. These advancements hold the promise of making weight-loss therapies more effective and accessible.
The cultural and political implications of GLP-1 drugs are just as significant. Public figures like RFK Jr. are questioning their role in addressing obesity, sparking debates about regulation and innovation. At the same time, societal perceptions of weight-loss medication are shifting, with advocates emphasizing that obesity should be viewed as a medical condition rather than a personal failing.
In summary, GLP-1 drugs are transforming health outcomes, reshaping industries, and sparking critical conversations about accessibility, affordability, and sustainability. While challenges remain, their potential to improve lives and change the landscape of obesity treatment is undeniable.